Suppression of Seasonal Increase in Serum Interleukin-5 is linked to the Clinical Efficacy of Immunotherapy for Seasonal Allergic Rhinitis

References

• Ricci M, Rossi O, Bertoni M, Matucci A. The impor-tance of TH2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993; 23: 360–9.
   Google Scholar
• Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone; implication for immune regulation. Immunol Today 1987; 8: 223–7.
   PubMedGoogle Scholar
• Spiegelberg HL, Beck L, Stevenson DD, Ishioka GY. Recognition of T-cell epitopes and lymphokine secre-tion by rye grass allergen Lolium perenne I-specific human T-cell clones. J Immunol 1994; 152: 4706–11.
   PubMedGoogle Scholar
• Kay AB, Ying S, Varney VA. Messenger RNA expres-sion of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimu-lating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775–8.
   Google Scholar
• Robinson DS, Hamid Q, Ying S, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Eng J Med 1992; 326: 298–304.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Ohashi Y, Kakinoki Y, Nakai Y. Im-munotherapy suppresses both Thl and Th2 responses by allergen stimulation, but suppression of Th2 re-sponse is a more important mechanism related to the clinical efficacy of immunotherapy for perennial aller-gic rhinitis. Scand J Immunol 1998; 48: 201–11.
   PubMed Web of Science ®Google Scholar
• Rothemberg ME, Peterson J, Stevens RL, et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced variability, accelerated hypo-density, and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311–6.
   PubMedGoogle Scholar
• Kay AB. T lymphocytes and their products in atopic allergy and asthma. Int Arch Allergy Appl Immunol 1991; 94: 189–93.
   PubMedGoogle Scholar
• Leung DYM, Geha RS. Regulation of the human IgE antibody response. Int Rev Immunol 1987; 2: 75–91.
   PubMedGoogle Scholar
• Schleimer RP, Sterbinsky SA, Kaiser J, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992; 148: 1086–92.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Nakai Y, Tanaka A, et al. Allergen-induced synthesis of interleukin-5, but not of IgE, is a key mechanism linked to symptomatic episodes of seasonal allergic rhinitis in sensitized individuals. Scand J Im-munol 1998; 47: 596–602.
   PubMedGoogle Scholar
• Brunet C, Bedard PM, Lavoie A, et al. Allergic rhinitis to ragweed pollen. 1. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 1992; 89: 76–86.
   Google Scholar
• Pence HL, Mitchell DQ, Greely RL. Immunotherapy for mountain cedar pollinosis: a double-blind con-trolled study. J Allergy Clin Immunol 1976; 58: 39–49.
   Google Scholar
• Ohashi Y, Tanaka A, Kakinoki Y, et al. Effect of immunotherapy on seasonal changes in serum-specific IgE and IgG4 in patients with pollen allergic rhinitis. Laryngoscope 1997; 107: 1270–5.
   PubMedGoogle Scholar
• Ohashi Y, Nakai Y, Kakinoki Y, et al. Immunother-apy affects the seasonal increase in specific IgE and interleukin-4 in the serum of patients with seasonal allergic rhinitis. Scand J Immunol 1997; 46: 67–77.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Nakai Y, Tanaka A, et al. Immunotherapy decreases seasonal rise in soluble CD23 in seasonal allergic rhinitis. Laryngoscope 1998; 108: 706–11.
   PubMedGoogle Scholar
• 41st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical re-search involving human subjects. Bull Pan Am Health Organ 1990; 24: 606–9.
   Google Scholar
• Ohashi Y, Ohno Y, Okamoto H, et al. Clinical evalua-tion of lumiward immunoassay system for measure-ment of Japanese cedar pollen-specific IgE antibodies. Pract Otol 1996; 89: 575–81.
   Google Scholar
• Chilosi M, Semenzato G, Cetto G, et al. Soluble inter-leukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant y-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–5.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Nakai Y, Sakamoto H, et al. Serum levels of soluble interleukin- 2 receptor in patients with peren-nial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996; 77: 203–8.
   PubMedGoogle Scholar
• Ohashi Y, Nakai Y, Okamoto H, et al. Significant correlation between symptom score and IgG4 antibody titer following long-term immunotherapy for perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997; 106: 483–9.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Nakai Y, Tanaka A, et al. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Asthma Allergy Immunol 1997; 79: 213–20.
   PubMedGoogle Scholar
• Ohashi Y, Nakai Y, Tanaka A, et al. Seasonal rise in interleukin-4 during pollen season is related to seasonal rise in specific IgE for pollens but not for mites. Acta Otolaryngol (Stockh) 1998; 118: 243–7.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FVV, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–8.
   Google Scholar
• Meuer SC, Hussey RE, Peta AC, et al. Cellular origin of interleukin 2 (IL-2) in man: evidence for stimulus-re-stricted IL-2 production by T4+ and T8+ T lymphocytes. J Immunol 1982; 129: 1076–9.
   PubMed Web of Science ®Google Scholar
• Farrar JJ, Benjamin WR, Hilfker ML, et al. The biochemistry, biology and role of interleukin-2 in the induction of cytotoxic T-cell antibody-forming B cell responses. Immunol Rev 1982; 63: 129–66.
   PubMed Web of Science ®Google Scholar
• Wladmann TA. The role of the multichain IL-2 recep-tor complex in the control of normal and malignant T-cell proliferation. Environ Health Perspect 1987; 75: 11–5.
   PubMedGoogle Scholar
• Robb RJ, Munck A, Smith KA. T-cell growth factor receptors. Quantitation, specificity and biological rele-vance. J Exp Med 1981; 154: 1455–74.
   Google Scholar
• Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated hu-man lymphoid cells in vitro. J Immunol 1985; 135: 3172–7.
   PubMed Web of Science ®Google Scholar
• Pui CH. Serum interleukin-2 receptor: clinical and biological implications. Leukemia 1989; 3: 323–4.
   PubMed Web of Science ®Google Scholar
• Kahaleh MB, Le Roy EC. Interleukin-2 in sclero-derma: correlation of serum level with extent of skin involvement and disease duration. Ann Inter Med 1989; 110: 446–50.
   PubMed Web of Science ®Google Scholar
• Balderas RS. Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice. J Immunol 1987; 139: 1496–550.
   PubMedGoogle Scholar
• Corrigan CJ, Hartnell A, Kay AB. T lymphocyte acti-vation in acute severe asthma. Lancet 1988; i: 1129–1132.
   Google Scholar
• Ohashi Y, Nakai Y, Okamoto H, et al. Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Im-munol 1996; 43: 680–6.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Nakai Y, Tanaka A, et al. Ten-year follow-up study of allergen-specific IgE and IgG4, soluble interleukin-2 receptor, interleukin-4, soluble intercellu-lar adhesion molecule-1 and soluble vascular cell adhe-sion molecule-1 in serum of patients treated with immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998; 47: 167–78.
   PubMedGoogle Scholar